These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 11099901

  • 1. Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy.
    Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI.
    Transfus Sci; 2000 Dec; 23(3):241-2. PubMed ID: 11099901
    [No Abstract] [Full Text] [Related]

  • 2. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
    Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI.
    Blood; 2001 Feb 01; 97(3):792-8. PubMed ID: 11157499
    [Abstract] [Full Text] [Related]

  • 3. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.
    Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI.
    Blood; 2000 May 01; 95(9):2975-82. PubMed ID: 10779448
    [Abstract] [Full Text] [Related]

  • 4. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.
    Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S.
    Blood; 1996 Jul 15; 88(2):705-13. PubMed ID: 8695819
    [Abstract] [Full Text] [Related]

  • 5. [Diagnosis and therapy of iron overload with desferrioxamine].
    Andres J, Stobbe H.
    Z Gesamte Inn Med; 1984 Apr 15; 39(8):167-9. PubMed ID: 6730593
    [Abstract] [Full Text] [Related]

  • 6. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
    al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV.
    Br J Haematol; 1992 Oct 15; 82(2):431-6. PubMed ID: 1419825
    [Abstract] [Full Text] [Related]

  • 7. Desferrioxamine in the management of dialysis hemosiderosis.
    Krumlovsky FA.
    Int J Artif Organs; 1982 Jul 15; 5(4):223-5. PubMed ID: 7118282
    [No Abstract] [Full Text] [Related]

  • 8. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH.
    Curr Top Hematol; 1978 Jul 15; 1():127-50. PubMed ID: 400529
    [No Abstract] [Full Text] [Related]

  • 9. Recent developments in iron chelation therapy.
    Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E.
    Klin Padiatr; 2007 Jul 15; 219(3):158-65. PubMed ID: 17525910
    [Abstract] [Full Text] [Related]

  • 10. Iron overload in cardiac valvular disease and pure red cell aplasia: treatment with desferrioxamine.
    Hehlmann R, Schmitz H, Krüger K.
    Int J Cardiol; 1984 Jun 15; 5(6):749-53. PubMed ID: 6235195
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Current concepts in the overall management of thalassemia.
    Propper RD.
    Ann N Y Acad Sci; 1980 Jun 15; 344():375-83. PubMed ID: 6930877
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of iron overload in adults with continuous parenteral desferrioxamine.
    Cooper B, Bunn HF, Propper RD, Nathan DG, Rosenthal DS, Moloney WC.
    Am J Med; 1977 Dec 15; 63(6):958-66. PubMed ID: 605917
    [Abstract] [Full Text] [Related]

  • 14. Iron overload? In sickle cell disease?
    Day S, Dancy R, Kelly K, Wang W.
    MCN Am J Matern Child Nurs; 1993 Dec 15; 18(6):330-5. PubMed ID: 8295522
    [No Abstract] [Full Text] [Related]

  • 15. Ability to determine the desferrioxamine-chelatable iron fractions of nontransferrin-bound iron using HPLC.
    Koba M, Słomka A, Bączek T, Marszałł MP, Zekanowska E.
    J Sep Sci; 2013 Feb 15; 36(4):665-9. PubMed ID: 23355397
    [Abstract] [Full Text] [Related]

  • 16. Effect of desferrioxamine B. A new iron eliminating agent, on cases of secondary haemosiderosis in children.
    el-Gholmy A, Khalifa AS, Rahman YA, el-Bagoury I.
    J Trop Med Hyg; 1969 Jan 15; 72(1):22-6. PubMed ID: 5773810
    [No Abstract] [Full Text] [Related]

  • 17. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R, Lund U, Caruso V, Fischer R, Janka GE, Magnano C, Engelhardt R, Dürken M, Nielsen P.
    Ann N Y Acad Sci; 2005 Jan 15; 1054():429-32. PubMed ID: 16339692
    [Abstract] [Full Text] [Related]

  • 18. [Iron-chelating treatment].
    Vullo C, Di Palma A, De Sanctis V, Borgatti L, Atti G.
    Haematologica; 1989 Oct 15; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract] [Full Text] [Related]

  • 19. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
    Srichairatanakool S, Thephinlap C, Phisalaphong C, Porter JB, Fucharoen S.
    Med Chem; 2007 Sep 15; 3(5):469-74. PubMed ID: 17897073
    [Abstract] [Full Text] [Related]

  • 20. [Isoferritin profile of serum ferritin in patient's with secondary hemosiderosis treated with desferrioxamine].
    Mariańska B, Eber M, Oberling F.
    Acta Haematol Pol; 1982 Sep 15; 13(3-4):65-72. PubMed ID: 7184299
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.